Eisai Pharmatechnology and Manufacturing Pvt. Ltd. and Eisai Pharmaceuticals India Pvt. Ltd, located at Visakhapatnam and Mumbai, respectively, have been amalgamated. Both are subsidiaries of Eisai Co. Ltd. (headquarters at Tokyo). The new entity is known as Eisai Pharmaceuticals India Pvt. Ltd.
Eisai Co. is a global R&D based pharmaceutical company.
As part of its commitment to the global initiative, Eisai has agreed to supply 2.2 billion diethylcarbamazinecitrate (DEC) 100 mg tablets free of charge to the World Health Organisation under the Mass Drug Administration (MDA) programme for eliminating lymphatic filariasis, said Managing Director of the new entity, Sanjit Singh Lamba.
ADVERTISEMENT
Eisai has commenced the supply of DEC tablets from its Visakhapatnam plant.